Skip to main content
Canna~Fangled Abstracts

Increased expression of CB2 receptor in the intestinal biopsies of children with inflammatory bowel disease

By June 18, 2022June 20th, 2022No Comments

. 2022 Jun 18.

doi: 10.1038/s41390-022-02109-5.

Online ahead of print.
Caterina Strisciuglio 1, Mara Creoli 2, Chiara Tortora 3, Massimo Martinelli 4, Erasmo Miele 4, Salvatore Paino 2, Livio Luongo 2 5, Francesca Rossi 3
Affiliations 

Abstract

Objectives: The Cannabinoid Receptor type 2 (CB2) is involved in inflammation and immune cell modulation. In previous studies, we demonstrated the association between the CNR2 rs35761398 polymorphism and the risk for pediatric inflammatory bowel disease (IBD). In this study, we analyzed the intestinal biopsies from Crohn disease (CD) and ulcerative colitis (UC) pediatric patients at the diagnosis to evaluate the expression of CB2 and several factors associated with IBD inflammatory pathways.

Methods: We enrolled five patients with CD, five with UC, and five controls (CTR). We analyzed ileum and rectum biopsies from patients of each group evaluating the expression of CB2, Toll-like receptor 4, interleukin-6, and interleukin-1β by western blot and immunofluorescence.

Results: Western blot analysis showed a significant increase of CB2 in the CD ileum and in the UC rectum biopsies and an increase of TLR4 in the UC rectum. We also observed a significant over-expression of the IL-6 in UC rectum. The immunofluorescence analysis confirmed western blot data, showing also a T-lymphocytes infiltration colocalized with CB2 expression in the CD ileum and UC rectum.

Conclusions: Our results show an upregulation of CB2 in pediatric IBD, which might have implications for drug discovery.

Impact: The Cannabinoid Receptor type 2 (CB2) is involved in the inflammation and modulation of the immune response in pediatric inflammatory bowel disease (IBD). CB2 receptor is more expressed in the inflamed intestine of pediatric IBD patients. CB2 could be used as a potential therapeutic target to reduce IBD-related inflammatory state in childhood.

References

    1. Nasser, Y., Bashashati, M. & Andrews, C. N. Toward modulation of the endocannabinoid system for treatment of gastrointestinal disease: FAAHster but Not “Higher”. Neurogastroenterol. Motil. 26, 447–454 (2014). – DOI
    1. Miller, A. M. et al. CB2 receptor-mediated migration of immune cells: it can go either way. Br. J. Pharm. 153, 299–308 (2008). – DOI
    1. Rossi, F. et al. Cannabinoid Receptor Type 2 functional variant influences liver damage in children with non-alcoholic fatty liver disease. PLoS One 7, e42259 (2012). – DOI
    1. Strisciuglio, C. et al. Cannabinoid Receptor 2 functional variant contributes to the risk for pediatric inflammatory bowel disease. J. Clin. Gastroenterol. 52, e37–e43 (2018). – DOI
    1. Cencioni, M. T. et al. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via Cb2 receptors. PLos One 5, e8688 (2010).

Leave a Reply